Clinical Trials in Pescara, Italy
19 recruiting
Showing 1–20 of 26 trials
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Not Applicable
Rehabilitation With Dual-task Exercises to Improve Balance in Patients With Parkinson's Disease
Parkinson Disease (PD), Postural Balance
G. d'Annunzio University74 enrolled1 locationNCT07013214
Recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium300 enrolled86 locationsNCT05160584
Recruiting
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS4,000 enrolled38 locationsNCT06459024
Recruiting
Phase 3
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Acute Myeloid LeukemiaRelapse/Recurrence
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS339 enrolled37 locationsNCT06713837
Recruiting
Phase 3
A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy
Multiple Myeloma
Pfizer1,116 enrolled88 locationsNCT05623020
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Scleroderma, Diffuse
Novartis Pharmaceuticals96 enrolled80 locationsNCT06655896
Recruiting
Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Multiple Myeloma
European Myeloma Network B.V.1,594 enrolled210 locationsNCT05243797
Recruiting
Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen304 enrolled192 locationsNCT04994717
Recruiting
Not Applicable
Physical Activity-based Intervention in Depressed Patients: Clinical, Neurophysiological, Epigenetic and Metabolic Correlates
Major Depressive Disorder (MDD)
IRCCS Centro San Giovanni di Dio Fatebenefratelli110 enrolled4 locationsNCT06989944
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
Nodal Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)300 enrolled36 locationsNCT05700149
Recruiting
Not Applicable
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Classical Hodgkin LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Fondazione Italiana Linfomi - ETS552 enrolled40 locationsNCT05934084
Recruiting
Phase 2
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Diffuse Large B Cell Non-Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS47 enrolled20 locationsNCT06835530
Recruiting
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS1,500 enrolled61 locationsNCT06008691
Recruiting
Phase 2Phase 3
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Karyopharm Therapeutics Inc501 enrolled57 locationsNCT04442022
Recruiting
Phase 3
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Crohn's DiseaseUlcerative Colitis
Takeda70 enrolled57 locationsNCT06100289
Recruiting
Prevention ICONA Dedicated Ensemble
HIV-1-infectionHIVPrEP+3 more
Fondazione ICONA5,000 enrolled53 locationsNCT07186244
Recruiting
Phase 3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Acute Lymphoblastic Leukemia, Pediatric
Martin Schrappe5,000 enrolled115 locationsNCT03643276